A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial)Masayuki Takeda, Mototsugu Shimokawa, Eiji Iwama et al.|Clinical Lung Cancer|2024Cited by 5